OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial
OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial
OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.